Regeneron Pharmaceuticals Q3 2026 Earnings Report

Regeneron Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: $15.99
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Regeneron Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $4.54 billion
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Regeneron Pharmaceuticals Announcement Details

• Quarter: Q3 2026
• Date: 10/30/2026
• Time: Before Market Opens
• Conference Call Date: Friday, October 30, 2026
• Conference Call Time: 8:30AM ET

Regeneron Pharmaceuticals (NASDAQ:REGN) is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder. The company also maintains a pipeline of investigational medicines and antibody-based therapies.

Founded in 1988 and headquartered in Tarrytown, New York, Regeneron serves patients and healthcare professionals in the United States and international markets through its commercial operations and partnerships. Leonard S. Schleifer, M.D., Ph.D., is the company’s co-founder, president and chief executive officer, while George D. Yancopoulos, M.D., Ph.D., is a co-founder and serves as president and chief scientific officer.